Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alpha-2a vs Cyclosporine in Refractory Behçet's Uveitis
NCT03209219Phase 3Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2017
- Primary completion
- Aug 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa-2a in Behçet's disease (BD) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Response Rate at 12 months, Complete Remission Rate at 12 months and 1 more. Started Jun 2017; status: completed.
02
Drugs
interferon alfa-2a
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT03209219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03209219.